Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model

Antiviral Research

Volumn 151, Issue , 2018, Pages 39-49

  Zhu, Wenjun ^a,b   Zhang, Zirui ^a,b   He, Shihua ^a   Wong, Gary ^a,b,c,d   Banadyga, Logan ^a,b   Qiu, Xiangguo ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Ebola virus; Mouse; Mouse adapted Marburg virus (variant Angola); Oral administration; T 705 (Favipiravir)

Indexed keywords

FAVIPIRAVIR; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FILOVIRUS INFECTION; MARBURGVIRUS; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VERO C1008 CELL LINE; VIRUS PARTICLE; ANIMAL; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; DRUG EFFECT; MARBURG HEMORRHAGIC FEVER; METABOLISM; ORAL DRUG ADMINISTRATION; SURVIVAL ANALYSIS; VERO CELL LINE; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE, INBRED BALB C; PYRAZINES; RNA, VIRAL; SURVIVAL ANALYSIS; VERO CELLS; VIRAL LOAD; VIRUS REPLICATION;

EID: 85041656192     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.01.011     Document Type: Article

References (26)

1. Arias, A., Thorne, L., Goodfellow, I., Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife, 3, 2014, e03679, 10.7554/eLife.03679.
2. Bixler, S.L., Duplantier, A.J., Bavari, S., Discovering drugs for the treatment of ebola virus. Curr. Treat. Options Infect. Dis. 9 (2017), 299–317.
3. Connor, J., Kobinger, G., Olinger, G., Therapeutics against filovirus infection. Curr. Top. Microbiol. Immunol., 2017 Jun 27, 10.1007/82_2017_12 [Epub ahead of print].
4. Feldmann, H., Sanchez, A., Geisbert, T.W., Filoviridae: Marburg and ebola viruses. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, sixth ed., 2013, Lippincott Williams & Wilkins, Philadelphia, 923–956.
5. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005), 981–986.
6. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100 (2013), 446–454.
7. Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous basepairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 50- Triphosphate towards influenza a virus polymerase. PLoS One, 8, 2013, e68347.
8. Johansen, L.M., Brannan, J.M., Delos, S.E., Shoemaker, C.J., Stossel, A., Lear, C., Hoffstrom, B.G., Dewald, L.E., Schornberg, K.L., Scully, C., Lehar, J., Hensley, L.E., White, J.M., Olinger, G.G., FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med., 5, 2013 190, ra179.
9. Madelain, V., Oestereich, L., Graw, F., Nguyen, T.H.T., de Lamballerie, X., Mentré, F., Günther, S., Guedj, J., Ebola virus dynamics in mice treated with favipiravir. Antivir. Res. 123 (2015), 70–77.
10. Martins, K.A., Jahrling, P.B., Bavari, S., Kuhn, J.H., Ebola virus disease candidate vaccines under evaluation in clinical trials. Expet Rev. Vaccine 15:9 (2016), 1101–1112, 10.1080/14760584.2016.1187566.
11. Mehedi, M., Groseth, A., Feldmann, H., Ebihara, H., Clinical aspects of Marburg hemorrhagic fever. Future Virol. 6 (2011), 1091–1106, 10.2217/fvl.11.79.
12. Mentré, F., Taburet, A.M., Guedj, J., Anglaret, X., Keïta, S., de Lamballerie, X., Malvy, D., Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis. 15:2 (2015), 150–151, 10.1016/S1473-3099(14)71047-3.
13. Nakayama, E., Saijo, M., Animal models for Ebola and Marburg virus infections. Front. Microbiol., 4, 2013, 267, 10.3389/fmicb.2013.00267.
14. Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., Günther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105 (2014), 17–22.
15. Olinger, G.G. Jr., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S.D., Johnson, A.K., Morton, J., Pauly, M., Whaley, K.J., Lear, C.M., Biggins, J.E., Scully, C., Hensley, L., Zeitlin, L., Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109 (2012), 18030–18035.
16. Picazo, E., Giordanetto, F., Small molecule inhibitors of Ebola virus infection. Drug Discov. Today 20 (2015), 277–286.
17. Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., Strong, J.E., Plummer, F., Corbett, C.R., Alimonti, J.B., Kobinger, G.P., Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med., 4, 2012 138, ra181.
18. Qiu, X., Wong, G., Audet, J., Cutts, T., Niu, Y., Booth, S., Kobinger, G.P., Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 88 (2014), 12703–12714.
19. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. Faseb. J. 22:3 (2008), 659–661.
20. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med., 13(3), 2016, e1001967.
21. Smee, D.F., Hurst, B.L., Egawa, H., Takahashi, K., Kadota, T., Furuta, Y., Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob. Chemother. 64 (2009), 741–746.
22. Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104 (2014), 153–155.
23. Warren, T.K., Wells, J., Panchal, R.G., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:7496 (2014), 402–405.
24. Warren, T.K., Jordan, R., Lo, M.K., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:7594 (2016), 381–385.
25. World Health Organization, Ebola Situation Report – 30 March 2016., 2016 http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016. (Accessed 5 August 2017)
26. Yen, H.L., Current and novel antiviral strategies for influenza infection. Curr Opin Virol. 18 (2016), 126–134 Jun.